2024 BrainChip Discussion, page-3856

First 3856 Last

Share
Profile

Follow
TomAndJerry

1,902 Posts.

439

24/03/24

09:44

Post #: 73030569
Share

Originally posted by DerAktienDude: ↑

I want this post to age poorly. Bad!

Investing has been pretty successful for me so far. At times selling stocks made me about 6 months of my salary and I've only sold being in the red for three times so far.

With BRN when I started investing pre-Renesas era I thought after selling the second ip license and hiring a new CEO that this one is fairly de-risked. All the due diligence I did seemed to pay off, even in the short-term already.

Sure, it's a pre revenue penny stock in an evolving space. However, the statements made by the management were so confident that anything but success seemed almost inevitable. What stuck to my mind was Anil Mankar's prediction "you will see a lot of up licensing going forward". That was 965 days ago.

Sean Hehir's revenue predictions and his statement to watch the financials eventuated in a share price drop to times where Akida literally wasn't even a thing.
AI exploded during that time with BRN being down around 80-95% of its ATH.

The cope in the other forum reaches levels of mentally ill people. Anyone that disagrees with their believes is personified evil. It reached the status of a cult that's normally reserved for ultra-religious people. They're online in this forum almost constantly scrapping the web for anything that might be related to BRN - even though it's clearly not.

Even though I'm invested heavily in this I have to face the reality. Statements from the management so far have never eventuated into something material. Not once. During the AI boom we performed like a magazine company. Would I invest in this company now if I'd heard of it for the first time? Not in a quadrillion years.

The only thing that's keeping me invested are my paper-losses and my hope for something to happen. I spent so much time putting in research for this company. I hope that I come across this post in a couple of years smurking at the share price and telling myself that my due diligence was good after all.

Expand

Great post.
So far there has only been promises.
I am looking forward to the day that it changes to something substantial.
Not really looking to read more rubbish news articles paid for by Brainchip aka shareholders.
Also not keen on silly roadshows only to be followed by a credit raise.
Neither interested in what was said in secret meetings, because look how that has helped the attendees!?

We all need that results that Sean has promised us ages ago.
Not downramping when you ask that, it is only a fair thing for shareholders to know and we deserve answers.

BRN Price at posting: 33.0¢ Sentiment: None Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

PYC

PYC commences new study on drug for eye condition Retinitis Pigmentosa type 11

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

MM1

Midas logs 17 spodumene pegmatite targets over 4km at Aylmer Project in Canada but drills while off

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

AZY

Antipa's Minyari Dome reveals gold up to 24g/t through drilling at key prospect

There are more pages in this discussion • 2,899 more messages in this thread...

First 3856 Last

Add BRN (ASX) to my watchlist

(20min delay)
Last 19.5¢		Change -0.005(2.50%)		Mkt cap ! $371.1M

Open	High	Low	Value	Volume
20.0¢	20.0¢	19.5¢	$165.5K	829.9K

Buyers (Bids)

No.	Vol.	Price($)
43	1808511	19.5¢

Sellers (Offers)

Price($)	Vol.	No.
20.0¢	625317	19

View Market Depth

No.	Vol.	Price($)
42	1807043	0.195
58	1875256	0.190
27	1259196	0.185
53	1629000	0.180
14	566998	0.175

Price($)	Vol.	No.
0.200	665317	20
0.205	551366	12
0.210	648081	17
0.215	451219	14
0.220	717003	21

Last trade - 10.24am 10/07/2024 (20 minute delay)

BRN (ASX) Chart

2024 BrainChip Discussion, page-3856

PYC commences new study on drug for eye condition Retinitis Pigmentosa type 11

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Midas logs 17 spodumene pegmatite targets over 4km at Aylmer Project in Canada but drills while off

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Antipa's Minyari Dome reveals gold up to 24g/t through drilling at key prospect

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

2024 BrainChip Discussion, page-3856

Top Stories

PYC commences new study on drug for eye condition Retinitis Pigmentosa type 11

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Midas logs 17 spodumene pegmatite targets over 4km at Aylmer Project in Canada but drills while off

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Antipa's Minyari Dome reveals gold up to 24g/t through drilling at key prospect

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News